Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-0557 + orlistat
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MK-0557 + orlistat is a combination therapy that was investigated for weight management in obese patients. MK-0557 is a neuropeptide Y5 receptor (NPY5R) antagonist that targets central counter-regulatory mechanisms related to the orexigenic hormone neuropeptide Y. Orlistat is a pancreatic lipase inhibitor that reduces the absorption of dietary fat in the intestine. The combination was studied to determine if NPY5R antagonism could enhance the weight loss efficacy of orlistat.
- Other names
- orlistat
02
Targets
NPY5R (Neuropeptide Y receptor type 5)PNLIP (Pancreatic triacylglycerol lipase)
Beyond the preview
Go deeper on MK-0557 + orlistat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-0557 + orlistat.